

## **Development of Tablet Formulations of Enteric Coated Esomeprazole with Acryl EZE**

Putta Rajesh Kumar<sup>\*1</sup>, Somashekar Shyale<sup>\*2</sup>, M. Mallikarjuna Gouda<sup>1</sup> and S. M. Shanta Kumar<sup>1</sup>

<sup>1</sup>Dept. of Pharmaceutics and Pharmaceutical Chemistry, V.L.College of Pharmacy, Raichur  
<sup>2</sup>H.S.B.P.V.T. Faculty of Pharmacy, Kashti, Maharashtra

---

### **ABSTRACT**

*Esomeprazole magnesium trihydrate tablets were formulated by directly compression and enteric coated with Acryl EZE. The rheological characteristics of powder beds were freely flowable and easily compressible. The Compressional parameters after enteric coating were found to be uniform and consistent. The hardness (Kg/cm<sup>2</sup>) was found in the range of 4.133±0.321 to 4.833±0.153. The enteric coated tablets were not disintegrated in simulated gastric fluid. The drug content in all formulations was found to be uniform and consistent. Accuracy and precision studies indicated drug content uniformity in tablet formulations. The acid uptake studies showed less than 5% acid uptake for all tablets indicated that the drug could be protected from degradation in gastric environment by acryl EZE enteric coating. In the In vitro drug release studies there is no loss during gastric phase. Later the study showed that tablets with lactose DC released higher than mannitol probably owing to its hydrophilicity and due to swelling of the super disintegrant. From the above findings it can conclude that an enteric coated Esomeprazole magnesium trihydrate tablet dosage form could be developed to deliver the drug in to proximal small intestine for more bio availability and to treat peptic ulcer.*

**Keywords:** Esomeprazole magnesium trihydrate, crospovidone, sodium starch glycollate, croscarmellose sodium and *In vitro* studies.

---

### **INTRODUCTION**

The term “peptic ulcer” refers to an ulcer in the lower part of esophagus or stomach or duodenum or in the jejunum after surgical anastomosis to the stomach or rarely in the ileum adjacent to a meckel’s diverticulum. Ulcers in the stomach or duodenum may be acute or chronic; both penetrate the muscularis mucosae but the acute ulcer shows no evidence of fibrosis.

The ulcers in stomach are called as gastric ulcers and the ulcers in the first portion of the intestine are called duodenal ulcers. One cause of peptic ulcer is bacterial infection, but some ulcers are caused by long term use of non steroidal anti-inflammatory agents (NSAID's) like aspirin, and ibuprofen. In a few cases cancerous tumors in the stomach or pancreas can cause ulcers. *Helicobacter pylori* (*H.pylori*) is a type of bacteria, researchers believe that it is responsible for the majority of peptic ulcers. *H.pylori* infection is common in the United States about 20% of people under 40 years old and half of these over 60 suffer from *H.pylori* infection. In India about 45% of people under 45 years suffer from peptic ulcer.

Peptic ulcer disease is a common clinical ailment, once thought to be caused by over secretion of acid and pepsin, an enzyme of the stomach that promotes digestion by breaking down proteins. Researchers have found, however, that although the injury caused by acid and pepsin is necessary for the formation of ulcers, acid secretion levels of the majority of patients with gastric or duodenal ulcers are normal. An ulcer is now known to be the result of an imbalance between aggressive and defensive mechanisms in the stomach and duodenum. Part of that imbalance can be attributed to infection by *H.pylori*.

An ulcer forms when there is an imbalance between aggressive factors, i.e. the digestive power of acid and pepsin and defensive factors, i.e. the ability of the gastric and duodenal mucosa to resist this power. This mucosal resistance constitutes the gastric mucosal barrier.

**Table 1: Drug candidates commonly used in the treatment of peptic ulcers**

Drugs	Short term	Maintenance
<b>H<sub>2</sub> receptor antagonists</b>		
Cimetidine	400 mg 12 h or 800 mg at night	400 mg at night
Ranitidine	150 mg 12 h or 300 mg at night	150 mg at night
Famotidine	20 mg 12 h or 40 mg at night	20 mg at night
Nizatidine	150 mg 12 h or 300 mg at night	150 mg at night
<b>Proton pump inhibitors</b>		
Esomeprazole	20-40 mg once daily	20 mg at night
Lansoprazole	30 mg once daily	15 mg at night
Pantoprazole	40 mg once daily	Not recommended
Rabeprazole	20 mg once daily	20 mg at night

Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion and are effective for treating all gastric acid-related disorders [1]. Esomeprazole magnesium trihydrate, the S-isomer of omeprazole, inhibits the gastric parietal H<sup>+</sup>/K ATPase irreversibly which involved in hydrochloric acid production in the stomach. It acts as proton pump inhibitor, used to treat gastroesophageal reflux disease (GERD), erosive esophagitis and gastric ulcer [2-3].

Esomeprazole is a substituted benzimidazole, used for the treatment of NSAIDs-associated gastric ulcer, *Helicobacter pylori* eradication and control of pathological hypersecretory conditions [4]. The stability of esomeprazole magnesium is a function of pH, it rapidly degrades in acidic media, but it has acceptable stability under alkaline conditions. At pH 6.8 (buffer), the half-life of the magnesium salt is about 19 hours at 25° C and about 8 hours at 37° C [5]. Esomeprazole has a half life of 1.25 ± 0.25 h and has a bioavailability of 48% when administered orally [6-7]. Esomeprazole is combined with antibiotics clarithromycin and amoxicillin or

metronidazole in 7-14 days eradication triple therapy of *Helicobacter pylori* infection where majority of peptic and duodenal ulcers were caused by *H. pylori* [8-9].

In the current research study directly compressed tablets of Esomeprazole magnesium trihydrate tablets were developed with various superdisintegrants, DC Lactose and DC Mannitol. Preliminary formulation development studies were conducted with varying concentrations of different superdisintegrants followed by rheological evaluation of powder blends. Further these are compressed in to tablets, optimized tablet formulations were enteric coated with Acryl EZE to protect the drug from harsh gastric conditions, to deliver drug in the duodenum which helps in improved bioavailability of Esomeprazole. Further various compression characteristics of the prepared tablets were studied. The acryl EZE enteric coated tablets were subjected for *in vitro* dissolution studies to study the actual drug release pattern.

## MATERIALS AND METHODS

### Active pharmaceutical ingredient and Reagents:

Esomeprazole magnesium trihydrate was procured from Aurobindo pharma limited, A.P, India). Crospovidone, Sodium starch glycolate, Croscarmellose sodium obtained from Danmed Pharmaceuticals Pvt Ltd, Hyderabad. Lactose DC and Mannitol DC were procured from SD Fine Chemicals Limited, Mumbai. Acryl EZE (Eudragit L 30 D55, Colorcon) was supplied by Medreich Limited, Bangalore. Other solvents and chemicals used in the research were of LR grade.

**Screening studies of super disintegrants and fillers for Esomeprazole directly compressible tablets:** Initially crospovidone, sodium starch glycolate and croscarmellose sodium were checked in 2.5, 5, 7.5 % to get a disintegration time of < 2 min. Trial formulations were developed as follows.

**Table 2 a): Formulation table for crospovidone containing tablets**

S.No	Ingredients (mg)	Formulations (mg)					
		1	2	3	4	5	6
1	Crospovidone	2.5	5.0	7.5	2.5	5.0	7.5
2	Talc:Mg.Sterate(2:1)	2	2	2	2	2	2
3	DC Lactose	95.5	93	90.5	-	-	-
4	DC Mannitol	-	-	-	95.5	93	90.5
5	Total Tablet Weight (mg)	100	100	100	100	100	100

**Table 2 b): Formulation table for Sodium starch glycolate containing tablets**

S.No	Ingredients (mg)	Formulations (mg)					
		1	2	3	4	5	6
1	Sodium starch glycolate	2.5	5.0	7.5	2.5	5.0	7.5
2	Talc:Mg.Sterate(2:1)	2	2	2	2	2	2
3	DC Lactose	95.5	93	90.5	-	-	-
4	DC Mannitol	-	-	-	95.5	93	90.5
5	Total Tablet Weight (mg)	100	100	100	100	100	100

**Table 2 c): Formulation table for Sodium starch glycolate containing tablets**

S.No	Ingredients (mg)	Formulations (mg)					
		1	2	3	4	5	6
1	Croscarmellose sodium	2.5	5.0	7.5	2.5	5.0	7.5
2	Talc:Mg.Sterate(2:1)	2	2	2	2	2	2
3	DC Lactose	95.5	93	90.5	-	-	-
4	DC Mannitol	-	-	-	95.5	93	90.5
5	Total Tablet Weight (mg)	100	100	100	100	100	100

**Esomeprazole magnesim trihydrate powder blends formulation for direct compression:**

The core tablets (tablet weight 100 mg) of Esomeprazole magnesium trihydrate were formulated containing 20 mg dose of drug. Formulation variables were, three different super disintegrants, crospovidone, sodium starch glycolate and croscarmellose sodium, to disintegrate the tablet in < 2 min, were used and the weight percent of the super disintegrants was optimized at 7.5 % and also two different directly compressible vehicles, Lactose and Mannitol were used as diluents. Talc and magnesium stearate in 2: 1 ratio was included to assist in free flowing of powder blend and smooth ejection of compressed tablet, at 2 % w/w.

**Table 3: Formulation table of Esomeprazole magnesium trihydrate tablets.**

S. No	Name of the Ingredient	Tablet Formulations (mg)					
		E 1	E 2	E 3	E 4	E 5	E 6
1	Esomeprazole magnesium trihydrate	20.670	20.670	20.670	20.670	20.670	20.670
2	Crospovidone	7.5	—	—	7.5	—	—
3	Sodium starch glycolate	—	7.5	—	—	7.5	—
4	Croscor mellose Sodium	—	—	7.5	—	—	7.5
5	Talc and Magnesium sterate (2:1)	2	2	2	2	2	2
6	Lactose DC	69.83	69.83	69.83	—	—	—
7	Mannitol DC	—	—	—	69.83	69.83	69.83
8	Total Tablet Weight (mg)	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>	<b>100</b>

**Method of preparation of Core tablet containing Esomeprazole magnesim trihydrate:**

The Esomeprazole magnesim trihydrate formulations were prepared by direct compression technology. Ingredients of E 1 to E 6 formulations were accurately weighed, milled and passed through sieve # 100/ 120 individually and then thoroughly blended in a cube mixer for 30 min. The uniformly blended powder bed was studied for the following rheological characteristics.

**Evaluation of rheological properties of powder bed:**

**Bulk density [10]:** Bulk density was determined (Konark instruments, India) by placing a fixed weight of powder/granules (100 G) blend in a measuring cylinder on bulk density testing unit (Konark Instruments, India) and the total volume was noted. Bulk density was calculated by using the formula.

$$\text{Bulk density} = \text{Total weight of powder} / \text{Total volume of powder}$$

Average of three densities of powder were taken and tabulated. (n=3)

**Tapped density [10]:** Tapped density was determined in a bulk density testing apparatus (Konark instruments, India) by placing the powder/granules blend in the measuring cylinder and the total volume of powder blend was noted before and after 100 tappings. Tapped density was calculated by using the formula.

$$\text{Tapped density} = \text{Total weight of powder} / \text{Total volume of powder after 100 tappings}$$

Average of three densities of powder were taken and tabulated. (n=3)

**Compressibility index [11]:** Compressibility index was determined by placing the powder/granules in a measuring cylinder and the volume ( $V_0$ ) was noted before tapping. After 100 tapping again volume ( $V$ ) was noticed.

$$\text{Compressibility index} = (1 - V / V_0) \times 100$$

$V_0$  = volume of powder/granules before tapping.

$V$  = volume of powder/granules after 100 tappings.

Average of three compressibility indices of powder/granule readings were taken.

**Angle of repose ( $^\circ\theta$ ) [11]:** Angle of repose was determined by measuring the height and radius of the heap of the powder/granule bed. A cut stem funnel was fixed to a stand and bottom of the funnel was fixed at a height of 3 cm from the horizontal plane. Powder/granule was placed in the funnel and allowed to flow freely. With the help of vernier calipers (Mitutoyo, Japan) the height and radius of the heap were measured and noted. Average of triplicate readings was computed (n = 3).

$$\text{Tan } \theta = h / r$$

$h$  = height of heap of powder/granule bed.

$r$  = radius of heap of powder/granule bed.

Average of three repose angles were taken and tabulated. (n=3)

**Preparation of powder blend and compression of tablet formulations of esomeprazole magnesium trihydrate:** The uniformly blended powder containing esomeprazole magnesium trihydrate and directly compressible vehicles of various tablet formulations from E 1 to E 6 were compressed into tablets on a 10 station tablet punching machine (PP1D, Chamunda) using 6 mm flat punches at a pressure of 4-6 kg/cm<sup>2</sup>. In each batch 250 tablets were prepared.

**Enteric Coating of esomeprazole magnesium trihydrate tablet formulations with Acryl EZE:** Esomeprazole is a gastric unstable drug, hence to protect it from degrading gastric acid the core tablets were film coated with an enteric coating polymer, Acryl EZE (Eudragit E100 SS). First, seal coat was prepared by dissolving HPMC (6 cps) and PEG 8000 in purified water with continuous stirring. Then slowly methylene chloride was added and the solution was filtered by passing through # 200 mesh. 25 % w/w of acryl EZE (Eudragit L 30 D55, Colorcon) was prepared by dispersing acryl EZE in a beaker containing purified water and stirred slowly for 20 minutes and passed through # 200 mesh. The tablets were enteric coated in a Neocoata coating pan (Neo Machine Manufacturing Company Pvt. Ltd, Kolkata) so as to build up 8 to 10 % weight. Inlet bed temperature was adjusted to 52  $\pm$  1  $^\circ\text{C}$  and the solution was atomized at 1.5 psi/bar. The pan was rotated at a speed of 22 rpm and the total coating time was 90 min.

**Table 4. Coating parameters used in enteric coating of Eesomeprazole magnesium tablets with Acryl EZE.**

Sl. no	Coating parameter	E 1	E 2	E 3	E 4	E 5	E 6
1	Coating polymer	Acryl EZE	Acryl EZE	Acryl EZE	Acryl EZE	Acryl EZE	Acryl EZE
2	Solvent	Purified water	Purified water	Purified water	Purified water	Purified water	Purified water
3	Solid % w/w	25	25	25	25	25	25
4	Bed Temperature (°C)	28-30	27-30	28-31	28-30	27-30	28-31
5	Inlet Temperature (°C)	52	51	50	52	51	50
6	Outlet Temperature (°C)	37	38	37	37	38	37
7	Atomization Pressure (psi/bar)	1.5	1.7	2.1	1.5	1.7	2.1
8	Pattern Air Pressure (psi/bar)	1.5	1.7	2.1	1.5	1.7	2.1
9	Pan Speed (rpm)	22	21	20	22	21	20
10	Pan Charge (g)	700	800	900	700	800	900
11	Baffles	05	05	05	05	05	05
12	Spray Gun to bed distance (inches)	25-27	25-27	25-27	25-27	25-27	25-27
13	Fluid nozzle (mm)	0.05	0.05	0.05	0.05	0.05	0.05
14	Fluid Delivery Rate (ml/min)	1ml/min	1ml/min	1ml/min	1ml/min	1ml/min	1ml/min
15	Drying Air Volume (cfm/m/h)	450 (850/m/h)	450 (850/m/h)	450 (850/m/h)	450 (850/m/h)	450 (850/m/h)	450 (850/m/h)
16	Spray equipment	Neocota coating pan	Neocota coating pan	Neocota coating pan	Neocota coating pan	Neocota coating pan	Neocota coating pan
17	Coating Time (min):						
a)	3% HPMC Subcoat	30	30	30	30	30	30
b)	7% Acryl EZE Enteric Coat	60	60	60	60	60	60
c)	Total (minutes)	90	90	90	90	90	90
18	Theoretical weight gain %	8.1	10	9.2	9.1	8.2	10

**Methods used for compressional parameters of Esomeprazole magnesium tablets:**

**Tablet weight variation** [12]: Ten tablets were randomly sampled and accurately weighed. Results are expressed as mean values  $\pm$  SD.

**Diameter test** [12]: The tablets were evaluated for their diameter using a vernier Caliper (Mitutoyo, Japan). Average of three readings were taken and tabulated ( $n = 3$ ).

**Tablet thickness** [12-13]: A vernier calipers (Mitutoyo, Japan) was used to determine thickness of randomly selected tablets ( $n=3$ ). Results obtained were tabulated as mean values  $\pm$  SD.

**Hardness test** [14]: The tablets were evaluated for their hardness using hardness tester (Pfizer, India). Average of three readings were taken and tabulated ( $n = 3$ ).

**Friability test** [15]: Roche Friabilator was used for testing the friability of the tablets. Five tablets were weighed accurately and placed in the tumbling chamber and rotated at 20 rpm for a period of 5 min. The tablets were removed, dedusted and accurately weighed. The percent weight loss was calculated

**Density measurement** [16]: The apparent density of the tablets was calculated from their volumes and masses. The volumes  $V$  of the tablets were calculated from their height  $h$  and radius  $r$  using micrometer. Volume of the tablets was calculated by using the following equation.  $V = \Pi \times r^2 \times h$

**Disintegration test** [17]: The disintegration time of core tablets was determined according to I.P. by placing one tablet in each of the six tubes of the basket and the assembly was suspended into a beaker containing 0.1 M HCl maintained at  $37 \pm 0.5^\circ\text{C}$  and operated for 2 h. Then 0.1 M HCl was replaced with pH 7.4 buffer solution and operated for further 1 h. Average of triplicate readings were computed.

**Determination of drug content** [13]: Randomly samples out 6 Core tablets of esomeprazole magnesium trihydrate were crushed into powder in a mortar and weight equivalent to 20 mg of drug was taken into a volumetric flask containing methanol and kept aside with constant shaking for 24 h on a rotary flask shaker (Konark instruments, Ambala cantonment, Haryana.) to extract the total drug present in the tablet. Then the absorbance of the solutions was measured after suitable dilution at 203.5 nm against drug devoid methanol as blank. Averages of triplicate readings were taken

**Acid uptake testing** [18]: In this method, six enteric coated esomeprazole magnesium trihydrate core tablets with Acryl EZE were weighed individually and placed in the disintegration basket tubes. The disintegration basket was immersed in 900 ml of 0.1 N hydrochloric acid and operated the apparatus for 2 h. The individual tablets that were still intact were then dried with a tissue paper and reweighed. The percent of weight increase was reported as percent acid uptake. Tablets that fully disintegrated during the testing were counted as having 100 % acid uptake. This method has been reported to provide an accurate measure of acid resistance of the enteric coating, and acid uptake values  $< 5\%$  suggests that the tablets would readily pass the acid phase of the delayed-release dissolution testing.

$$FA (\%) = (T_f - T_i / T_i) \times 100$$

FA (%): Percent Acid uptake,

T<sub>f</sub>: Final tablet weight (mg)

T<sub>i</sub>: Initial tablet weight (mg)

### ***In vitro* dissolution studies of esomeprazole magnesium trihydrate core tablets [19]:**

The release of esomeprazole magnesium from enteric coated tablets was determined by using dissolution rate test apparatus (Six Station Electrolab, India). The dissolution test was performed using 900 ml of 0.1 N HCl for first 2 h and later the assembly was lifted and the dissolution fluid was replaced with 900 mL of pH 7.4 phosphate buffer solution. The medium was stirred at 100 rpm at a temperature of 37 ± 0.5°C. Samples of 1 ml were withdrawn periodically up to eight hours and the volume was replaced with fresh medium to maintain the sink conditions. The samples were suitably diluted and the absorbances were measured at 203.5 nm for esomeprazole using U.V. 1700 (Pharmaspec Shimadzu, Japan). All the studies were carried out in triplicate and the average was considered (n = 3).

## **RESULTS**

**Table 5. Disintegration time Studies of Esomeprazole trial tablet formulations containing DC Lactose and DC Mannitol**

DC Lactose				DC Mannitol			
Sl. No.	Superdisintegrant	%	DT (sec)	Sl. No.	Superdisintegrant	%	DT (sec)
1	Crospovidone	2.5	14.58	1	Crospovidone	2.5	23.14
2	Crospovidone	5.0	11.32	2	Crospovidone	5.0	20.04
3	Crospovidone	7.5	10.63	3	Crospovidone	7.5	17.88
4	Sodium starch glycolate	2.5	14.14	4	Sodium starch glycolate	2.5	22.59
5	Sodium starch glycolate	5.0	10.61	5	Sodium starch glycolate	5.0	19.73
6	Sodium starch glycolate	7.5	7.21	6	Sodium starch glycolate	7.5	15.65
7	Croscarmellose sodium	2.5	14.36	7	Croscarmellose sodium	2.5	21.99
8	Croscarmellose sodium	5.0	10.68	8	Croscarmellose sodium	5.0	19.04
9	Croscarmellose sodium	7.5	8.63	9	Croscarmellose sodium	7.5	16.01

**Table 6. Rheological properties of Esomeprazole magnesium trihydrate powder bed (n= 3).**

Formulation Parameter	E1	E2	E3	E4	E5	E6
Compressibility Index %	16.0	17.4	18.1	18.8	17.9	16.0
Bulk density gm/cc	0.508	0.500	0.472	0.357	0.370	0.400
Tapped density gm/cc	0.606	0.625	0.577	0.411	0.451	0.484
Angle of repose (°Ø)	33.65	31.54	29.20	28.28	29.59	31.10



**Table 7: Compressional characteristics of Esomeprazole magnesium trihydrate tablets:**

Formulation	Weight Variation (mg)	Diameter (mm)	Thickness (mm)	Hardness (kg/cm <sup>2</sup> )	Drug content in pH 7.4 (mg)	Disintegration time in pH 7.4 (sec)	Density (g/cc)
E-1	102.1± 1.010	6.08± 0.020	2.30± 0.015	4.13± 0.321	19.790± 0.091	90.85± 0.600	1.52± 0.015
E-2	104.6± 0.901	6.073± 0.031	2.32± 0.025	4.43± 0.058	19.948± 0.045	62.22± 0.170	1.55± 0.019
E-3	104.5± 0.897	6.073± 0.012	2.35± 0.012	5.23± 0.153	19.869± 0.045	74.19± 0.050	1.53± 0.023
E-4	105.3± 0.851	6.060± 0.020	2.48± 0.023	4.40± 0.265	19.738± 0.091	96.49± 0.040	1.35± 0.021
E-5	103.3± 0.995	6.073± 0.033	2.43± 0.017	4.50± 0.10	19.948± 0.045	66.84± 0.310	1.46± 0.017
E-6	107.7± 0.826	6.060± 0.020	3.12± 0.032	4.83± 0.153	19.738± 0.046	83.13± 0.480	1.19± 0.011

*All the core tablets did not disintegrated in 0.1 N HCl for first 2 h.*

**Table 8. Acid uptake study of Esomeprazole magnesium trihydrate enteric coated tablets:**

Sl.no	Formulation	Tablet Initial Weight mg (T <sub>i</sub> )	Tablet Final Weight mg (T <sub>f</sub> )	Percent acid Up take (FA %)
1	E 1	102.683	105.832	3.07±0.897
2	E 2	104.567	107.950	3.24±0.980
3	E 3	104.40	108.567	3.99±0.689
4	E 4	105.501	108.250	2.61±0.919
5	E 5	103.533	106.417	2.78±0.984
6	E 6	107.450	110.567	2.90±0.561

**Table 9. In vitro dissolution study of enteric coated Esomeprazole magnesium trihydrate tablets containing Pharmatose DCL 11. (n=3).**

Sl. no.	Time (min)	Absorbance (n=3)	Esomeprazole concentration (mg)	Cum.amount of Esomeprazole (mg)	Esomeprazole Cumulative % release
1	0	0	0	0	0
2	5	0.026	1.866	4.394	22.20
3	10	0.096	6.803	11.197	56.58
4	30	0.026	1.795	17.008	85.94
5	45	0.019	1.370	18.378	92.86
6	60	0.007	0.425	18.803	95.01
7	90	0.001	0.094	18.898	95.49
8	120	0.002	0.142	19.039	96.21
9	180	0.001	0.118	19.157	96.80
10	240	0.001	0.165	19.323	97.64
11	300	0.002	0.118	19.441	98.24
12	360	0.002	0.118	19.559	98.83
13	420	0.001	0.118	19.677	99.43
14	480	0.000	0.000	19.677	99.43

**Table 10. In vitro dissolution study of enteric coated Esomeprazole magnesium trihydrate tablets containing Mannogem EZ. (n=3)**

Sl. no.	Time (min)	Absorbance (n=3)	Esomeprazole concentration (mg)	Cum. amount of Esomeprazole (mg)	Esomeprazole Cumulative % release
1	0	0	0.000	0.000	0.00
2	5	0.020	1.417	2.622	13.28
3	10	0.075	5.315	7.937	40.21
4	30	0.044	3.142	14.764	74.79
5	45	0.022	1.559	16.323	82.69
6	60	0.021	1.488	17.811	90.23
7	90	0.003	0.213	18.024	91.31
8	120	0.004	0.307	18.331	92.86
9	180	0.002	0.165	18.496	93.70
10	240	0.002	0.165	18.661	94.54
11	300	0.002	0.118	18.780	95.13
12	360	0.001	0.094	18.874	95.61
13	420	0.002	0.165	19.039	96.45
14	480	0.002	0.118	19.157	97.05

## DISCUSSION

The Preliminary Esomeprazole formulations showed disintegration time of less than 2 min which helps for immediate release of drug after rupturing of Acryl EZE coat in the alkaline pH of duodenum. Compressibility index of the directly compressible Esomeprazole magnesium trihydrate powder blends of core 1 to core 6 were found to be in between 16 to 18.8. The bulk density of core formulation powder blend is in between 0.357 to 0.508 and tapped density is from 0.411 to 0.625. The angle of repose ( $^{\circ}\theta$ ) was found to be in the range of 28.28 to 33.64. The rheological characteristics of directly compressible Esomeprazole magnesium trihydrate powder blend indicating that the powder beds of core formulations are freely flowable and easily compressible.

Further the directly compressible powder blend containing esomeprazole was compressed into compacts in a rotary tablet compression machine (PP1D, Chamunda) (n= 500). Later, the compressed tablets were enteric coated with Acryl EZE solution in a Neocota pan for 90 min. Enteric coated esomeprazole magnesium trihydrate core tablets were studied for various compressional parameters. The thicknesses (mm) of core 1 to core 6 tablets before enteric coating and after enteric coating with acryl EZE were found to be uniform and consistent and an increase in coat thickness of 0.1 mm to 0.2 mm were observed. Similarly diameters of uncoated and coated tablets were found to be uniform. The hardness ( $\text{Kg/cm}^2$ ) of core 1 to core 6 tablets was to be between found to be  $4.133\pm 0.321$  to  $4.833\pm 0.153$ . The friability of core 1 to core 6 uncoated tablets was found to be minimum. The results of disintegration time (sec) of enteric coated core 1 to core 6 showed that the tablets did not disintegrate in 0.1N HCl and the same when continued with phosphate buffer of pH 7.4 the tablets were found to disintegrated within  $96.49\pm 0.042$  sec (Table 1). The drug content studies of Core1 to core 6 tablets in methanol and phosphate buffer showed that almost 96.88 % to 99.74 % of Esomeprazole magnesium trihydrate was present.

Accuracy studies of Esomeprazole magnesium trihydrate tablets indicated that 99.68 to 97.37 % drug was recovered and a precision range from 0.017 to 0.052 indicates drug content uniformity and consistency in all the tablet formulations. Esomeprazole magnesium trihydrate core tablets

after enteric coating with acryl EZE were studied for acid uptake, to evaluate the efficiency of acryl EZE as enteric coating polymer to protect the acid liable esomeprazole in SGF. The results of all core tablet formulations showed acid uptake values in the range of 2.61 to 3.99 which are less than 5 indicating significant protection of drug by acryl EZE enteric coating. The *in vitro* dissolution study of core tablets showed that more than 90 % of drug was released within 60 min, although lactose DC contained tablets showed 5 % higher release than mannitol within 60 min. There is no drug release or loss during gastric phase i.e in 0.1 N HCl of 1.2 pH for first 2 h due to enteric coating which protects the drug from degradation due to acidic pH.

Studies on the rheological properties of angle of repose, bulk density, tapped density and compressibility index of the directly compressible esomeprazole magnesium trihydrate powder blend showed that the powder beds are freely flowable and are suitable for direct compression. After compression the core tablets of esomeprazole were of adequate strength and when enteric coated in Neocota pan using Acryl EZE the surface was found to be smooth and uniform. Studies on compression characteristics of esomeprazole magnesium core tablets indicated that, the weight variation, diameter, thickness, hardness and friability of prepared core tablets were uniform and reproducible. The tablets did not disintegrate in 0.1 N HCl however; they disintegrated within 96.49 sec when the study was continued in phosphate buffer pH 7.4. The drug content in all core formulations was found to be uniform and consistent. Accuracy and precision studies of core tablet formulations in UV Spectrophotometer indicated the accurate and precise drug content uniformity of esomeprazole magnesium trihydrate in tablet formulations. The acid uptake studies of enteric coated esomeprazole magnesium trihydrate tablets with Acryl EZE showed less than 5% acid uptake for all tablets which indicates that the drug could be protected from degradation in gastric environment and it can be successfully delivered to proximal part of small intestine. *In vitro* drug release studies results suggest that the excipient lactose DC releases higher than mannitol probably owing to its hydrophilicity and due to swelling and wicking action of the super disintegrant.

From the above research findings it can conclude that an enteric coated Esomeprazole magnesium trihydrate oral tablet dosage form could be developed by using superdisintegrants with direct compression technique to deliver the acid unstable drug safely in duodenum to achieve better bio availability and for better localized peptic ulcer treatment.

## CONCLUSION

Studies on the rheological properties of esomeprazole magnesium trihydrate powder blend showed that the powder beds are freely flowable and are suitable for direct compression. The enteric coated tablets using Acryl EZE showed smooth and uniform surface. Compression characteristics of esomeprazole magnesium core tablets indicated that, the weight variation, diameter, thickness, hardness and friability of prepared core tablets were uniform and reproducible. The tablets did not disintegrate in 0.1 N HCl however; they disintegrated within 96.49 sec when the study was continued in phosphate buffer pH 7.4. The drug content in all core formulations was found to be uniform and consistent. The acid uptake studies showed less than 5% acid uptake for all tablets which indicates that the drug could be protected from gastric environment and it could be successfully delivered to duodenum. *In vitro* drug release studies results suggest that the excipient lactose DC releases higher than mannitol probably owing to its hydrophilicity and due to swelling action of the super disintegrant.

From the above studies the enteric coated Eesomeprazole magnesium trihydrate oral tablet dosage form could be developed with direct compression technique to deliver the acid unstable drug safely in duodenum for better bio availability and localized therapy.

## REFERENCES

- [1] <http://emedicine.medscape.com/article/173727-overview> online accessed on 17/08/2010.
- [2] JC Mucklow. Martindale: The Complete Drug Reference, 32nd ed, Pharmaceutical Press, Great Britain, 2002, pp 1225-1226.
- [3] Putta Rajesh Kumar; Somashekar Shyale; M Mallikarjuna Gouda and SM Shanta Kumar. *J. Chem. Pharm. Res*, 2010, 2, 484.
- [4] R Vachhani; G Olds; V Velanovich. *Expert rev gastroenterol hepatol*. 2009, 3, 15.
- [5] <http://www.rxlist.com/nexium-drug.htm> online accessed on 11/12/2010.
- [6] [http://www.rxlist.com/cgi/generic3/Eesomeprazole\\_cp.htm](http://www.rxlist.com/cgi/generic3/Eesomeprazole_cp.htm) online accessed on 04/11/2008.
- [7] <http://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?id=1677#nlm34089-3>; for esomeprazole online accessed on 11/11/2008.
- [8] <http://en.wikipedia.org/wiki/Eesomeprazole>. online accessed on 8/07/2010.
- [9] Putta Rajesh Kumar; Somashekar Shyale; M Mallikarjuna Gouda and SM Shanta Kumar. *Research J. Pharm. and Tech*. 2011, 4, 242.
- [10] [http://www.pharmacopeia.cn/v29240/usp29nf24s0\\_c616.html](http://www.pharmacopeia.cn/v29240/usp29nf24s0_c616.html) online accessed on 15/06/2010.
- [11] [http://www.pharmacopeia.cn/v29240/usp29nf24s0\\_c1174.html](http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1174.html) online accessed on 14/06/2010.
- [12] Mina Ibrahim Tadros. *European Journal of Pharmaceutics and Biopharmaceutics*. 2010, 74, 332.
- [13] Putta Rajesh Kumar; Rajesh Tatavarthi; M Mallikarjuna Gouda; Somashekar Shyale and SM Shanta Kumar. *International Journal of Pharmaceutical Sciences Review and Research*. 2011, 6, 56.
- [14] Yagnesh Bhatt; Anand Deshmukh; Maulesh Joshi; Suhas Nalle and Raviprakash Paladi. *Int. J. Ph. Sci*. 2009, 1, 310.
- [15] Singh Chhater; Kumar Rajesh; Agarwal Kshitij and RK Nema. *International journal of pharmaceutical sciences and nanotechnology*. 2009, 2, 443.
- [16] A Streubel; J Siepmann and R Bomeier. *European journal of pharmaceutics*. 2003, 18, 37.
- [17] Indian pharmacopoeia, The Indian pharmacopoeia commission, Ghaziabad. 2007; 3 ed, vol-1: pp 177-178.
- [18] R Charles; Cunningham and Kurt A Fegely. *Pharmaceutical technology*. 2001, 11, 36.
- [19] S Ramkanth; M Alagusundaram; K Gnanaprakash; C Madhusudhana Chetty; K Mallikarjuna Rao; Y Sudhakar and Annie Baby. *Journal of Pharmacy Research*. 2010, 3, 1263.